About The Study: This study estimates that approximately one-third of U.S. adults without diabetes who were eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) were excluded from clinical trials supporting these medications’ safety and effectiveness. Until there is evidence from high-quality postmarketing studies, the FDA should consider updating labeling to advise caution on generalizing the safety and effectiveness of GLP-1 and GLP-1/GIP to populations excluded from pivotal trials.

Affordability in Canada affects not just groceries but also medications, with 1 in 20 people unable to take their medications as prescribed because of cost, found new research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241024.

New Curtin University research challenges views on screen time, revealing factors such as parental mental health and the type of screen being used may have some impact on child development.